Literature DB >> 25883022

In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.

Chen Li Chew1, Andrea Lunardi1, Federico Gulluni2, Daniel T Ruan1, Ming Chen1, Leonardo Salmena1, Michiya Nishino3, Antonella Papa1, Christopher Ng1, Jacqueline Fung1, John G Clohessy1, Junko Sasaki4, Takehiko Sasaki4, Roderick T Bronson5, Emilio Hirsch2, Pier Paolo Pandolfi6.   

Abstract

UNLABELLED: The phosphatases PTEN and INPP4B have been proposed to act as tumor suppressors by antagonizing PI3K-AKT signaling and are frequently dysregulated in human cancer. Although PTEN has been extensively studied, little is known about the underlying mechanisms by which INPP4B exerts its tumor-suppressive function and its role in tumorigenesis in vivo. Here, we show that a partial or complete loss of Inpp4b morphs benign thyroid adenoma lesions in Pten heterozygous mice into lethal and metastatic follicular-like thyroid cancer (FTC). Importantly, analyses of human thyroid cancer cell lines and specimens reveal INPP4B downregulation in FTC. Mechanistically, we find that INPP4B, but not PTEN, is enriched in the early endosomes of thyroid cancer cells, where it selectively inhibits AKT2 activation and in turn tumor proliferation and anchorage-independent growth. We therefore identify INPP4B as a novel tumor suppressor in FTC oncogenesis and metastasis through localized regulation of the PI3K-AKT pathway at the endosomes. SIGNIFICANCE: Although both PTEN and INPP4B can inhibit PI3K-AKT signaling through their lipid phosphatase activities, here we demonstrate lack of an epistatic relationship between the two tumor suppressors. Instead, the qualitative regulation of PI3K-AKT2 signaling by INPP4B provides a mechanism for their cooperation in suppressing thyroid tumorigenesis and metastasis. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25883022      PMCID: PMC4497843          DOI: 10.1158/2159-8290.CD-14-1347

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  34 in total

1.  Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.

Authors:  Joanne Ngeow; Jessica Mester; Lisa A Rybicki; Ying Ni; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

2.  Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate.

Authors:  York Posor; Marielle Eichhorn-Gruenig; Dmytro Puchkov; Johannes Schöneberg; Alexander Ullrich; André Lampe; Rainer Müller; Sirus Zarbakhsh; Federico Gulluni; Emilio Hirsch; Michael Krauss; Carsten Schultz; Jan Schmoranzer; Frank Noé; Volker Haucke
Journal:  Nature       Date:  2013-07-03       Impact factor: 49.962

Review 3.  PTEN loss in the continuum of common cancers, rare syndromes and mouse models.

Authors:  M Christine Hollander; Gideon M Blumenthal; Phillip A Dennis
Journal:  Nat Rev Cancer       Date:  2011-04       Impact factor: 60.716

4.  Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates.

Authors:  Adeeti V Ullal; Vanessa Peterson; Sarit S Agasti; Suan Tuang; Dejan Juric; Cesar M Castro; Ralph Weissleder
Journal:  Sci Transl Med       Date:  2014-01-15       Impact factor: 17.956

5.  Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression.

Authors:  Rachelle L Dillon; Richard Marcotte; Bryan T Hennessy; James R Woodgett; Gordon B Mills; William J Muller
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

6.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.

Authors:  Christina Gewinner; Zhigang C Wang; Andrea Richardson; Julie Teruya-Feldstein; Dariush Etemadmoghadam; David Bowtell; Jordi Barretina; William M Lin; Lucia Rameh; Leonardo Salmena; Pier Paolo Pandolfi; Lewis C Cantley
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

7.  Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice.

Authors:  Ericka Diallo-Krou; Jingcheng Yu; Lesley A Colby; Ken Inoki; John E Wilkinson; Dafydd G Thomas; Thomas J Giordano; Ronald J Koenig
Journal:  Endocrinology       Date:  2009-09-24       Impact factor: 4.736

8.  PTEN-deficient tumors depend on AKT2 for maintenance and survival.

Authors:  Y Rebecca Chin; Xin Yuan; Steven P Balk; Alex Toker
Journal:  Cancer Discov       Date:  2014-05-16       Impact factor: 39.397

9.  The effect Akt2 deletion on tumor development in Pten(+/-) mice.

Authors:  P-Z Xu; M-L Chen; S-M Jeon; X-d Peng; N Hay
Journal:  Oncogene       Date:  2011-07-11       Impact factor: 9.867

10.  Epigenetic inactivation of inositol polyphosphate 4-phosphatase B (INPP4B), a regulator of PI3K/AKT signaling pathway in EBV-associated nasopharyngeal carcinoma.

Authors:  Jessie Wai-Fong Yuen; Grace Tin-Yun Chung; Samantha Wei-Man Lun; Chartia Ching-Mei Cheung; Ka-Fai To; Kwok-Wai Lo
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

View more
  40 in total

1.  INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.

Authors:  Darien E Reed; Kevan M Shokat
Journal:  Mol Cancer Res       Date:  2017-02-14       Impact factor: 5.852

2.  Cancer: Precise control of localized signals.

Authors:  Vuk Stambolic
Journal:  Nature       Date:  2015-05-27       Impact factor: 49.962

3.  mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide.

Authors:  Akinobu Matsumoto; Alessandra Pasut; Masaki Matsumoto; Riu Yamashita; Jacqueline Fung; Emanuele Monteleone; Alan Saghatelian; Keiichi I Nakayama; John G Clohessy; Pier Paolo Pandolfi
Journal:  Nature       Date:  2016-12-26       Impact factor: 49.962

4.  Inactivating Frameshift Mutation of INPP4B Encoding a PI3K Pathway Phosphatase in Gastric and Colorectal Cancers.

Authors:  Eun Ji Choi; Min Sung Kim; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2016-04-11       Impact factor: 3.201

5.  Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining.

Authors:  Junior Tayou
Journal:  Cell Oncol (Dordr)       Date:  2018-04-20       Impact factor: 6.730

6.  A basal-enriched microRNA is required for prostate tumorigenesis in a Pten knockout mouse model.

Authors:  Xiying Fan; Glen A Bjerke; Kent Riemondy; Li Wang; Rui Yi
Journal:  Mol Carcinog       Date:  2019-09-12       Impact factor: 4.784

7.  Quantitative Lipid Imaging Reveals a New Signaling Function of Phosphatidylinositol-3,4-Bisphophate: Isoform- and Site-Specific Activation of Akt.

Authors:  Shu-Lin Liu; Zhi-Gang Wang; Yusi Hu; Yao Xin; Indira Singaram; Sukhamoy Gorai; Xin Zhou; Yoonjung Shim; Jung-Hyun Min; Liang-Wei Gong; Nissim Hay; Jin Zhang; Wonhwa Cho
Journal:  Mol Cell       Date:  2018-08-30       Impact factor: 17.970

Review 8.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

9.  INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency.

Authors:  Thanh-Trang T Vo; David A Fruman
Journal:  Cancer Discov       Date:  2015-07       Impact factor: 39.397

Review 10.  PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.

Authors:  Zahra Nozhat; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.